Bernard Macatangay, MD

Bernard Macatangay, MD

Contact

Campus: 3550 Terrace St

Office: S827 Scaife Hall

Pittsburgh, PA 15261

Ph: 412-383-1272

macatangaybj@upmc.edu

Education

  • B.S., Biology, University of the Philippines
  • Doctor of Medicine, University of the Philippines, College of Medicine

Academic Affiliation

  • Assistant Professor, Medicine
  • Assistant Professor, Infectious Diseases and Microbiology
  • Assistant Professor, Immunology

About Research

lmmunoregulatory mechanisms can influence many aspects of the body's immune responses to different antigens, and can control inflammatory responses, thereby preventing pathology caused by persistent immune activation and inflammation. The Macatangay laboratory focuses on various immunoregulatory pathways in different inflammatory states, especially in HIV infection. Specifically, the lab aims to define the role of different immunoregulatory mechanisms in: the inflammatory state associated with chronic HIV infection; HIV persistence; and various HIV immunotherapeutic strategies, such as in therapeutic vaccination. By using specimens obtained from the various studies at the Pittsburgh Treatment and Evaluation Unit (PTEU), the AIDS Clinical Trials Group (ACTG), and the Multicenter AIDS Cohort Study/Women's Interagency HIV Study (MACS/WIHS Combined Cohort Study), the lab assesses the immunophenotype and frequencies of regulatory immune cell subsets. It also analyzes specific suppressive function and components of regulatory pathways to further understand the influence of specific immunoregulatory mechanisms in HIV pathogenesis and persistence. In doing so, Dr. Macatangay aims to improve existing or develop new immunotherapeutic strategies for the control of chronic HIV-associated inflammation and/or for the functional cure of HIV.
 

Selected Publications

Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA. A randomized, placebo-controlled, pilot clinical trial of dipyridamole to decrease HIV-associated chronic inflammation. The Journal of Infectious Diseases. 2019; 221(10): 1598-1606.
 
Macatangay BJC, Gandhi RT, Jones RB, McMahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR. T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy. AIDS. 2020; 34(1): 15-24.
 
Rocco J, Mellors JW, Macatangay BJ. Regulatory T cells: the ultimate HIV reservoir?. Journal of Virus Eradication. 2018; 4(4): 209-214.
 
Rocco JM, York Z, Shen C, Shiboski C, Cyriaque-Webster J, McLaughlin J, Borowski L, Chen H, Aberg JA, Dittmer DP, Ghannoum M, Rinaldo CR, Macatangay B. Oral cytokine levels are more linked to levels of plasma and oral HIV-1 RNA than with CD4+ T cell counts in people with HIV. Open Forum Infectious Diseases. 2020; 7(3).
 
Macatangay BJ, Riddler S, Wheeler N, Spindler J, Lawani M, Hong F, Buffo M, Whiteside T, Kearney M, Mellors JW, Rinaldo C. Therapeutic vaccination with dendritic cells loaded with autologous HIV-1-infected apoptotic cells. J Inf Dis. 2016; 213(9): 1400-9.
 
Macatangay BJC, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR. Regulatory T cell suppression of Gag-specific CD8+ T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. Regulatory PLoS One. 2010.